Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CORRECTION: Lipocine Q4 EPS $(0.03), Inline

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 121.43 percent decrease over earnings of $0.14 per share from the same period last year.
byHappy Mohamed
March 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 121.43 percent decrease over earnings of $0.14 per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Akoya Biosciences Announces Preliminary Financial Results For Q4 And FY23 And Provides 2024 Outlook; Sees Q4 Revenue $25.5M-$26.5M Vs $26.28M Est.; FY23 Revenue $95.6M-$96.6M Vs $96.6M Est.; Expects FY24 Revenue To Grow 20%+

By Benzinga Newsdesk
January 7, 4:18 PM
Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023

AKYA